<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1130-6343</journal-id>
<journal-title><![CDATA[Farmacia Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Farm Hosp.]]></abbrev-journal-title>
<issn>1130-6343</issn>
<publisher>
<publisher-name><![CDATA[Grupo Aula Médica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1130-63432022000600004</article-id>
<article-id pub-id-type="doi">10.7399/fh-13293</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estabilidad del colirio de insulina para el tratamiento de úlceras corneales refractarias]]></article-title>
<article-title xml:lang="en"><![CDATA[Stability of insulin eye drops in the treatment of refractory corneal ulcers]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cuartero-Martínez]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hermelo-Vidal]]></surname>
<given-names><![CDATA[Gonzalo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro-Balado]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-García]]></surname>
<given-names><![CDATA[Ángeles]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Barcia]]></surname>
<given-names><![CDATA[Miguel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Otero-Espinar]]></surname>
<given-names><![CDATA[Francisco José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández-Ferreiro]]></surname>
<given-names><![CDATA[Anxo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mondelo-García]]></surname>
<given-names><![CDATA[Cristina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Investigación Sanitaria Santiago de Compostela Gupo de Farmacología Clínica ]]></institution>
<addr-line><![CDATA[Santiago de Compostela ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Santiago de Compostela Departamento de Farmacología, Farmacia y Tecnología Farmacéutica ]]></institution>
<addr-line><![CDATA[Santiago de Compostela ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Área Sanitaria de Santiago de Compostela e Barbanza Servicio de Farmacia ]]></institution>
<addr-line><![CDATA[Santiago de Compostela ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Área Sanitaria de Santiago de Compostela e Barbanza Servicio de Análisis clínicos ]]></institution>
<addr-line><![CDATA[Santiago de Compostela ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>46</volume>
<numero>6</numero>
<fpage>335</fpage>
<lpage>339</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1130-63432022000600004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1130-63432022000600004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1130-63432022000600004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Determinar y comparar la estabilidad físico-química y microbiológica de dos colirios de insulina 25 UI/ml elaborados con suero fisiológico o balanced salt solution bajo diferentes condiciones de conservación durante 120 días.  Método: Los colirios se elaboraron por triplicado con insulina Actrapid® 100 Ul/ml y balanced salt solution o suero fisiológico como vehículo, y fueron conservados a temperatura ambiente (25 °C), en nevera (2-8 °C) o congelador (&#8211;20 °C) durante 120 días. Se determinó la concentración de insulina mediante cromatografía liquida de ultra alta resolución, la osmolalidad y el pH a días 0, 3, 7, 15, 30, 60, 90 y 120. Asimismo, se extrajeron muestras para estudios microbiológicos en los días 0, 15, 30, 60, 90 y 120.  Resultados: La formulación elaborada con suero fisiológico mantuvo la concentración de insulina por encima del 90% con respecto a la inicial tras 120 días de estudio en todas las condiciones de temperatura. En el caso del colirio elaborado con balanced salt solution, la concentración se mantuvo estable en ambiente y congelador tras 120 días, aunque en nevera descendió por debajo del 90% a día 90 de estudio. Los valores de osmolalidad y pH se mantuvieron constantes en ambas formulaciones y condiciones de conservación. No se observó crecimiento microbiológico en ninguna de las muestras retiradas.  Conclusiones: El colirio de insulina 25 UI/ml elaborado con suero fisiológico es estable 120 días, conservado tanto a temperatura ambiente como en nevera o congelador, protegido de la luz. Con balanced salt solution permanece estable 120 días a temperatura ambiente y congelador, reduciéndose el periodo de validez a 90 días en el caso de la conservación en nevera.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To determine and compare the physicochemical and microbiological stability of two 25 IU/mL insulin eye drop formulations made with normal saline and a balanced salt solution, respectively, stored for 120 days under various conditions.  Method: Eye drops were compounded in triplicate with 100 IU/mL Actrapid® insulin and either normal saline or a balanced salt solution as vehicles, and they were stored alternatively at room temperature (25 °C), in a refrigerator (2-8 °C) or in a freezer (&#8211;20 °C) for 120 days. Insulin concentrations were determined by ultra-high resolution liquid chromatography, and osmolality and pH values were measured at days 0, 3, 7, 15, 30, 60, 90 and 120. Likewise, samples were extracted for microbiological studies on days 0, 30, 60, 90 and 120.  Results: The formulation made with normal saline maintained insulin concentrations above 90% of the baseline level after 120 days across all temperature conditions. In the case of the balanced salt solution-based eye drops, insulin concentration when stored at room temperature or in the freezer remained stable after 120 days, although insulin concentration when stored in the refrigerator fell below 90% on day 90 of the study. Osmolality and pH values remained constant in both formulations and across all storage conditions. No microbiological growth was observed in any of the samples.  Conclusions: 25 IU/mL insulin eye drops made with normal saline remain stable for 120 days whether they are stored at room temperature, in a refrigerator or in a freezer, provided that they are protected from light. When made with a balanced salt solution, they remain stable for 120 days at room temperature and in a freezer, their shelf life being reduced to 90 days in the case of storage in a refrigerator.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Insulina]]></kwd>
<kwd lng="es"><![CDATA[Úlceras corneales]]></kwd>
<kwd lng="es"><![CDATA[Estabilidad]]></kwd>
<kwd lng="es"><![CDATA[Formulación magistral]]></kwd>
<kwd lng="es"><![CDATA[Oftalmología]]></kwd>
<kwd lng="es"><![CDATA[Soluciones oftálmicas]]></kwd>
<kwd lng="en"><![CDATA[Insulin]]></kwd>
<kwd lng="en"><![CDATA[Corneal ulcers]]></kwd>
<kwd lng="en"><![CDATA[Stability]]></kwd>
<kwd lng="en"><![CDATA[Pharmaceutical compounding]]></kwd>
<kwd lng="en"><![CDATA[Ophthalmology]]></kwd>
<kwd lng="en"><![CDATA[Ophthalmic Solutions]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kern]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ulcerative keratitis]]></article-title>
<source><![CDATA[Vet Clin North Am Small Anim Pract]]></source>
<year>1990</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>643-66</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of Cryopreserved Amniotic Membrane Transplantation in Corneal Ulceration: A Meta-Analysis]]></article-title>
<source><![CDATA[Cornea]]></source>
<year>2019</year>
<volume>38</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>454-62</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farahani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Dwarakanathan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infectious corneal ulcers]]></article-title>
<source><![CDATA[Dis--Mon DM]]></source>
<year>2017</year>
<volume>63</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>33-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Medeiros]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Santhiago]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology of Corneal Scarring in Persistent Epithelial Defects After PRK and Other Corneal Injuries]]></article-title>
<source><![CDATA[J Refract Surg]]></source>
<year>2018</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-64</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaidyanathan]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Hopping]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[HY]]></given-names>
</name>
<name>
<surname><![CDATA[Somani]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
<name>
<surname><![CDATA[Ronquillo]]></surname>
<given-names><![CDATA[YC]]></given-names>
</name>
<name>
<surname><![CDATA[Hoopes]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Persistent Corneal Epithelial Defects: A Review Article]]></article-title>
<source><![CDATA[Med Hypothesis Discov Innov Ophthalmol J]]></source>
<year>2019</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>163-76</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ziaei]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Wound healing in the eye: Therapeutic prospects]]></article-title>
<source><![CDATA[Adv Drug Deliv Rev]]></source>
<year>2018</year>
<volume>126</volume>
<page-range>162-76</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sacchetti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lambiase]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of neurotrophic keratitis]]></article-title>
<source><![CDATA[Clin Ophthalmol Auckl NZ]]></source>
<year>2014</year>
<volume>8</volume>
<page-range>571-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wróbel-Dudzi&#324;ska]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suchodo&#322;a-Ratajewicz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kosior-Jarecka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rymgay&#322;&#322;o-Jankowska]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Efficacy of Platelet-Rich Plasma in the Treatment of Neurotrophic Corneal Ulcer]]></article-title>
<source><![CDATA[J Ophthalmol]]></source>
<year>2018</year>
<volume>2018</volume>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wirostko]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Human growth hormone promotes corneal epithelial cell migration in vitro]]></article-title>
<source><![CDATA[Cornea]]></source>
<year>2015</year>
<volume>34</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>686-92</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Carneiro]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Boschero]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[MJA]]></given-names>
</name>
<name>
<surname><![CDATA[Velloso]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of insulin in the tear film and insulin receptor and IGF-1 receptor on the human ocular surface]]></article-title>
<source><![CDATA[Invest Ophthalmol Vis Sci]]></source>
<year>2002</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>963-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz-Valle]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Burgos-Blasco]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gegúndez-Fernández]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[García-Caride]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Puebla-García]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Peña-Urbina]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Topical insulin for refractory persistent corneal epithelial defects]]></article-title>
<source><![CDATA[Eur J Ophthalmol]]></source>
<year>2021</year>
<volume>31</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>2280-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aynsley]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of insulin in the treatment of corneal ulcers]]></article-title>
<source><![CDATA[Br J Ophthalmol]]></source>
<year>1945</year>
<volume>29</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>361-3</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ahem]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mustapha]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mohd Noh]]></surname>
<given-names><![CDATA[UK]]></given-names>
</name>
<name>
<surname><![CDATA[Bastion]]></surname>
<given-names><![CDATA[MLC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized Controlled Trial of Topical Insulin for Healing Corneal Epithelial Defects Induced During Vitreoretinal Surgery in Diabetics]]></article-title>
<source><![CDATA[Asia-Pac J Ophthalmol Phila Pa]]></source>
<year>2017</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>418-24</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bastion]]></surname>
<given-names><![CDATA[MLC]]></given-names>
</name>
<name>
<surname><![CDATA[Ling]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Topical insulin for healing of diabetic epithelial defects?: A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients]]></article-title>
<source><![CDATA[Med J Malaysia]]></source>
<year>2013</year>
<volume>68</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>208-16</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano-Giménez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Contreras-Macías]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García-Bernal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fobelo-Lozano]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin eye drops for treating corneal ulcer in a non-diabetic patient: regarding a case]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2020</year>
<volume>44</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>297-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galvis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Niño]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Tello]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grice]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Topical insulin in neurotrophic keratopathy after resection of acoustic neuroma]]></article-title>
<source><![CDATA[Arch Soc Espanola Oftalmol]]></source>
<year>2019</year>
<volume>94</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>100-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Dan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insulin Promotes Corneal Nerve Repair and Wound Healing in Type 1 Diabetic Mice by Enhancing Wnt/&#946;-Catenin Signaling]]></article-title>
<source><![CDATA[Am J Pathol]]></source>
<year>2020</year>
<volume>190</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2237-50</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bartlett]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Slusser]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Turner-Henson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Atchison]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pillion]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toxicity of insulin administered chronically to human eye in vivo]]></article-title>
<source><![CDATA[J Ocul Pharmacol]]></source>
<year>1994</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>101-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="book">
<collab>Committee for Medicinal Products for Human Use</collab>
<source><![CDATA[Guideline on bioanalytical method validation]]></source>
<year>2015</year>
<publisher-name><![CDATA[European Medicines Agency]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lund]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[The Pharmaceutical CODEX: Principles &amp; Practice of Pharmaceutics]]></source>
<year>2009</year>
<edition>12.ª ed</edition>
<publisher-loc><![CDATA[New Delhi, India ]]></publisher-loc>
<publisher-name><![CDATA[CBS Publishers &amp; Distributors]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Real Farmacopea Española]]></source>
<year>2005</year>
<edition>3.ª ed</edition>
<page-range>1899-902</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="book">
<collab>Estados Unidos Mexicanos</collab>
<source><![CDATA[Farmacopea de los Estados Unidos Mexicanos]]></source>
<year>2011</year>
<volume>Vol. II</volume>
<edition>10.ª ed</edition>
<page-range>2402-6</page-range><publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Publicaciones e Impresiones de Calidad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="book">
<collab>The Stationary Office</collab>
<source><![CDATA[British Pharmacopoeia]]></source>
<year>2009</year>
<page-range>9134-44</page-range><publisher-loc><![CDATA[Londres ]]></publisher-loc>
<publisher-name><![CDATA[The Stationary Office]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castro-Balado]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[González-López]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco-Méndez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Requerimientos básicos para la elaboración de colirios]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Fernández-Ferreiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Formulación Magistral Oftálmica Antiinfecciosa]]></source>
<year>2019</year>
<page-range>63-70</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Sociedad Española de Farmacia Hospitalaria]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz-Valle]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Burgos-Blasco]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rego-Lorca]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Puebla-García]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-García]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Benítez-Del-Castillo]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea]]></article-title>
<source><![CDATA[Acta Ophthalmol (Copenh)]]></source>
<year>2022</year>
<volume>100</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e912-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Registro Unificado de Empresas de Sustancias Activas]]></source>
<year></year>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha técnica Dorzolamida/Timolol Cinfa 20 mg/ml + 5 mg/ml colirio en solución]]></source>
<year></year>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sheskey]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Handbook of pharmaceutical excipients]]></source>
<year>2009</year>
<edition>6.ª ed</edition>
<page-range>203-5</page-range><publisher-loc><![CDATA[Londres ]]></publisher-loc>
<publisher-name><![CDATA[Pharmaceutical Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Modi]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Gadge]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pawar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Ingole]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical challenges with excipients in insulin formulations and role of concentrated insulin]]></article-title>
<source><![CDATA[Int J Basic Clin Pharmacol]]></source>
<year>2019</year>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>821-6</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Final report on the safety assessment of sodium p-chloro-m-cresol, p-chloro-m-cresol, chlorothymol, mixed cresols, m-cresol, o-cresol, p-cresol, isopropyl cresols, thymol, o-cymen-5-ol, and carvacrol]]></article-title>
<source><![CDATA[Int J Toxicol]]></source>
<year>2006</year>
<volume>25</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>29-127</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
